Original Research ArticleInternational Journal of Advances in Medicine

Publication:
Clinical effectiveness of co-amoxiclav in upper respiratory tract infections: results from a large multicenter real-world evidence study

Int J Adv Med. 2026;13(6):378-385.DOI10.18203/2349-3933.ijam20263710

Read online (HTML) View on the journal's website(opens in a new tab)

Abstract

Background Upper respiratory tract infections (URTIs) are among the most common reasons for outpatient consultations and antibiotic prescribing. Although many URTIs are viral, bacterial infections and secondary bacterial complications often require antimicrobial treatment. Co-amoxiclav is widely used for bacterial respiratory infections; however, large-scale real-world evidence (RWE) remains limited. This study evaluated the effectiveness and prescribing patterns of co-amoxiclav in routine clinical practice.

Methods This multicenter, retrospective, medical record-based RWE study included patients with URTIs who received co-amoxiclav across participating centers. Demographic characteristics, prescribing patterns, and treatment outcomes were evaluated in pediatric (≤12 years) and adult (>12 years) populations. Clinical outcomes were categorized as cure, improvement, or no improvement.

Results A total of 12,986 patients were included, comprising 1,116 pediatric and 11,870 adult patients. Unspecified URTI was the predominant diagnosis (81.6%), followed by tonsillitis, acute otitis media (AOM), pharyngitis, sinusitis, and laryngitis. Suspension formulations were prescribed more frequently in pediatric patients, whereas tablet formulations predominated among adults. Twice-daily dosing was the most commonly prescribed regimen across age groups. Overall clinical success (cure plus improvement) was achieved in 12,970 patients (99.88%). Complete clinical cure was documented in 12,295 patients (94.7%), while 675 patients (5.2%) showed clinical improvement and only 16 patients (0.1%) reported no improvement. Clinical cure rates were comparable between pediatric and adult populations (93.8% vs. 94.8%, respectively).

Conclusions Co-amoxiclav demonstrated high rates of clinical cure and overall treatment success in patients with URTIs across pediatric and adult populations, supporting its effectiveness in routine clinical practice when appropriately prescribed for suspected bacterial respiratory infections.

Keywords

Affiliations

  1. Department of ENT and HNS, BC Roy Post-graduate institute of Pediatric sciences, Kolkata, West Bengal, India
  2. SSNK Medical College, Kopargaon, Ahmednagar, Maharashtra, India
  3. Shobha, Hospital, Jalgaon, Maharashtra, India
  4. Medical Affairs Team, Alkem Laboratories, Mumbai, Maharashtra, India
  5. Medical Division, Alkem Laboratories Ltd Mumbai, India

Full item record